Adding the numbers, since they settle part of this. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

That is the short version; the long version is somebody else's post.

One thing that is still open after carl_compliance’s answer:

How often to repeat it, because quarterly seems to be the convention and I cannot find the reasoning?

Dr.PeteFamMed said:

With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…

Adding the part of the answer the thread has not reached. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

Reporting back.

Took the whole panel in rather than the one flagged line, and the conversation lasted two minutes instead of generating three more tests.

andrew_nyc said:

The liver data is among the strongest non-weight findings in the class.

Agreed, and reference ranges are laboratory-specific. Comparing your number to somebody else's range, or to a screenshot from another country, is how people convince themselves something is wrong.